ABIVAX Société Anonyme's (ABVX) Equal Weight Rating Reiterated at Morgan Stanley

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock had its "equal weight" rating reissued by investment analysts at Morgan Stanley in a research report issued on Thursday, Marketbeat.com reports. They currently have a $12.00 price objective on the stock. Morgan Stanley's price target suggests a potential upside of 62.82% from the stock's previous close.

Several other brokerages have also issued reports on ABVX. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of "Buy" and a consensus target price of $38.00.

ABIVAX Société Anonyme Price Performance

Shares of ABVX stock traded down $0.01 during trading hours on Thursday, hitting $7.37. 121,012 shares of the company's stock traded hands, compared to its average volume of 121,849. The stock's 50 day simple moving average is $6.74 and its 200 day simple moving average is $8.46. ABIVAX Société Anonyme has a 12 month low of $5.50 and a 12 month high of $16.63.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC grew its stake in ABIVAX Société Anonyme by 190.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock worth $11,078,000 after purchasing an additional 991,781 shares during the period. Franklin Resources Inc. grew its position in shares of ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock worth $10,732,000 after buying an additional 141,710 shares during the period. Nantahala Capital Management LLC increased its stake in shares of ABIVAX Société Anonyme by 45.7% in the 4th quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company's stock valued at $10,512,000 after acquiring an additional 450,413 shares in the last quarter. Millennium Management LLC lifted its position in shares of ABIVAX Société Anonyme by 44.2% during the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock valued at $6,816,000 after acquiring an additional 285,542 shares during the period. Finally, Citadel Advisors LLC boosted its stake in ABIVAX Société Anonyme by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company's stock worth $6,264,000 after acquiring an additional 389,247 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.